Project management services for a pre-IND meeting keep the preparation work visible before the team sits down with FDA. They connect the questions leaders want answered with the evidence, owners, decisions, and deadlines that have to come together. They do not replace regulatory strategy or scientific judgement. When several functions move at once, a shared plan shows gaps and dependencies early enough to act on them.

Discuss your program planning needs

What should project management services cover before a pre-IND meeting?

Leaders should expect a planning framework that turns the meeting into coordinated work. Scientific, regulatory, clinical, quality, manufacturing, and executive contributors each hold part of the picture. The project job is to assemble those inputs around a clear purpose. Keep a trace from each question to its evidence, resolve dependencies, and put decisions in front of the right person on time.

That does not mean an external project manager decides what the science shows, interprets FDA requirements, or promises a meeting outcome. The organisation's regulatory and scientific leads own those judgements. Project management supports them by naming who must contribute and when a decision is due. It also shows what information is still open and how a change in one area moves the rest of the plan.

The distinction matters for executives. A readiness effort should produce more than a schedule or a pile of documents. It should make the path to the meeting governable. The team knows the purpose, leaders can see material risks, and contributors have a practical way to finish and review their work. Teams that want to see how this fits a wider operating model can review MustardSeed's operational PMO services and its foundational PMO services.

Why does pre-IND preparation need an integrated plan?

A pre-IND meeting is a decision-oriented conversation, not just a date on a calendar. The team needs a shared view of what it wants to learn and which questions need FDA input. It also needs to know what information supports those questions and which internal choices must be made first. If those pieces live in separate functional trackers, important handoffs stay hidden until late in preparation.

A scientific lead may be revising a rationale while a regulatory colleague refines the meeting questions. A manufacturing workstream may be checking whether a process description is current, while executives weigh programme priorities. Those tasks are connected. A change in assumptions or scope can move the wording and the evidence references. It can also move the review sequence and the decision schedule. The plan should show those relationships without replacing each function's specialist work.

An integrated plan typically brings together:

• Purpose and outcomes: the decisions or clarifications the organisation wants from the meeting, approved by its scientific and regulatory leaders.
• Questions and supporting evidence: a clear link between each proposed question and the information the team expects to discuss.
• Workstreams and owners: named functional leads, contributors, reviewers, and decision-makers for each deliverable.
• Dependencies and review windows: the order in which inputs, drafts, reviews, approvals, and meeting materials need to happen.
• Risks and open decisions: issues with a named owner, a response date, and an escalation path.

For some biologic products, FDA's Office of Therapeutic Products treats a pre-IND as a Type B meeting. It schedules the meeting within 60 days of a granted request and allots 60 minutes. OTP says a package for that hour should hold no more than 10 questions, counting sub-questions. A typical package is 50 to 100 pages. The package is due no later than 30 days before the meeting or a written-response date. Those figures are a planning input, not a rule for every FDA center or product. Confirm the current procedure with the team's regulatory lead and the relevant FDA page. Start at the FDA OTP pre-IND meetings page.

How can leaders define a useful readiness outcome?

Start with the decision the organisation needs to support. A vague goal such as "get ready for FDA" is hard to manage because it does not tell contributors what complete means. The accountable team should state what it expects to accomplish at the meeting. It should also state what must be ready to support that purpose. Scientific and regulatory content belongs to the relevant experts. The program plan makes the work and decisions around that content explicit.

Leaders can turn the purpose into a short set of planning questions:

1. What are the most important questions the organisation wants to discuss?
2. Which internal decisions must be made before the meeting, and who has authority to make them?
3. What information does the team expect to use to explain its position?
4. Which topics are unresolved, and what evidence or specialist input could clarify them?
5. What would the team need to record and assign after the meeting?

Then turn the answers into conditions someone can check. The team may decide that each proposed question has an owner and a reviewed rationale. It should also have linked supporting material and a recorded approval status. Another condition may be that material assumptions and open issues are visible to the executive sponsor. These are management controls, not a universal checklist of FDA requirements. Each organisation sets them with its regulatory and scientific leads.

Clear outcomes also limit scope drift. If someone proposes a new analysis, document, or discussion topic, test it against the agreed purpose. Then decide whether it adds a real dependency or should be handled separately. A PMO can show the effect on timing, workload, and decisions. The right leaders can then choose on purpose.

Which workstreams and handoffs should the plan make visible?

The workstream map should reflect the programme, not a generic template. Depending on the asset and the meeting objectives, contributors may include regulatory affairs, nonclinical and clinical science, and CMC or manufacturing. Quality, data, legal, finance, and senior leadership may also need a seat. Not every team needs every function. The question is whether the necessary expertise and approvals are in the room, not whether a standard list is filled in.

For each workstream, capture the deliverable or input and one owner. Also name the contributors, the reviewer or approver, the due dates, and the dependencies. Say how the team will know the work is ready for review. "Draft complete" means different things across functions. A definition of done might say the document is internally consistent and the source material is identified. The named reviewer has also accepted it for the next stage. The scientific or regulatory lead sets any content-specific acceptance criteria.

Handoffs need particular attention. A reviewer needs time and a stable version to give useful feedback. A decision-maker needs a short description of the choice and the options. They also need the implications and the deadline. If one person is the bottleneck for several approvals, the schedule should show that constraint instead of assuming every review can happen at once.

Executives can test the plan with one question. Could someone outside the day-to-day work name the current owner, the next milestone, and the unresolved decision for each critical item? If the answer is unclear, tighten the ownership or the status definitions. A structured PMO can help set that governance through strategic PMO support. A biotech team can also use this guide to PMO setup for a biotech startup.

How should the team connect questions, evidence, and decisions?

Use a question-to-evidence register as a coordination tool, not a scientific assessment. Regulatory and scientific owners decide which questions to ask, whether the supporting information is adequate, and how to present the organisation's position. The register helps the wider team see whether those pieces have been assembled and reviewed.

For each proposed question, record a short working version and the rationale. Also record the evidence the lead expects to reference, the owner, the reviewer, the approval status, and any open gap. If the question depends on several workstreams, record those dependencies. Keep version control so a change to a question can be traced to the materials and approvals it affects.

A filled register is not proof that the evidence is complete or persuasive. Use it to prompt a specific review. Is the source material identified? Has the accountable expert confirmed the link between the question and the evidence? Is an assumption still open? Does the document set use consistent terms and current versions? These checks make ownership visible and leave technical authority with the right specialists.

When several initiatives share people, the same approach helps leaders see capacity and shared dependencies. MustardSeed describes project cycle management as a broader planning discipline for work that spans more than one initiative. That discipline can show shared capacity, but it does not define the scientific content of a pre-IND discussion. Confirm the scope of any specific programme with the responsible experts.

How can a realistic timeline protect review quality?

Build the schedule back from the planned meeting. Do not simply divide the remaining days among deliverables. Start with the work that must be finished and the sequence of inputs. Then mark the decision points and the review capacity you actually have. Then add time for revisions. Also add time for issues that could change a draft or its supporting material.

A useful high-level sequence might include:

1. Align on purpose and governance. Confirm the intended outcomes, decision rights, workstream owners, meeting assumptions, and escalation route.
2. Map questions and inputs. Have regulatory and scientific leads shape the questions and identify the material needed to support team discussion.
3. Develop and review work products. Sequence drafting, functional input, cross-functional review, and approval with named owners and adequate review windows.
4. Resolve open issues. Track evidence gaps, conflicting assumptions, resource constraints, and decisions that may affect readiness.
5. Prepare the meeting team. Confirm roles, materials, internal alignment, and a process to capture decisions and actions.
6. Close the loop. After the meeting, record the outcomes, assign follow-up work, and connect actions to the wider programme plan.

The sequence is a management framework, not a prescribed FDA timetable. Actual timing depends on the programme and the meeting pathway. It also depends on how mature the information is and how the organisation reviews work. Regulatory leads should verify the applicable procedures and any relevant dates. A schedule should leave enough time for a real review, not just a convenient end date.

Use milestone dates to expose dependencies rather than create false precision. If a critical input is uncertain, show a range or a decision point and say what would move the date. If leaders compress the timeline, make the trade-off explicit: which review step changes, what risk increases, and who accepts that exposure. A credible plan supports a decision. It does not hide uncertainty.

What should executives see in readiness reporting?

Reporting should separate activity from readiness. A high share of completed tasks can hide an unresolved question or a delayed approval. It can also hide a dependency that blocks the next step. An executive view should show what is on track and what is at risk. It should also show which decision is due and what help is needed.

A concise status update can include:

• Milestone forecast: current forecast, movement since the last review, and the reason for any change.
• Critical path: the few deliverables or decisions that govern readiness, not every routine task.
• Top risks and issues: impact, owner, response, due date, and escalation status.
• Decisions required: the question for leadership, options, accountable decision-maker, and latest useful decision date.
• Readiness conditions: the agreed conditions and their status, with open items stated plainly.
• Capacity and dependencies: resource conflicts or other programmes competing for the same specialists.

Define status terms before reporting begins. "At risk" should name a credible threat to a milestone or an agreed condition. It should not mean a general worry. Each red or amber item should have an owner and a next action. Leaders also need to tell a genuine blocker from an item that only needs ordinary follow-up.

A dashboard cannot certify regulatory readiness. It is an aid to governance. Technical and regulatory leads decide whether content is suitable. Executive sponsors decide how to respond to material business risks. Teams that need a steady operating rhythm can read about MustardSeed's embedded operational project management and its PMO assessment approach.

Discuss project planning support with MustardSeed.

Which risks commonly disrupt the preparation effort?

Many readiness problems are coordination failures, not a shortage of effort. Teams may start drafting before they agree on the questions. They may also assume another function owns an input, or find that the reviewer cannot meet the turnaround. A risk log makes these concerns actionable. Record a cause, a likely effect, an owner, a response, and a review date.

Consider these common patterns:

• Questions change late. Track decisions that could shift the focus of the meeting and check their effect on related material.
• Evidence is hard to locate or reconcile. Assign an owner to name the authoritative source and resolve differences with the subject-matter lead.
• Reviews are treated as a formality. Schedule real review windows and say which feedback needs a resolution or an escalation.
• Key people are overcommitted. Surface capacity conflicts early and ask leaders to set priority, add support, or revise timing.
• Approvals are ambiguous. Record who recommends, who reviews, and who makes the final internal decision.
• Scope expands without a decision. Assess the consequences of new work before adding it to the critical plan.
• Meeting follow-up is not owned. Decide in advance how notes, decisions, and action owners will be captured and moved into programme governance.

Escalation should be timely and proportionate. A working team can resolve routine coordination issues. A change to programme assumptions belongs with the right decision-maker. So does a material evidence gap or a conflict that needs executive priority. The point of escalation is to get a decision while there is still time to act. It is not to assign blame after a milestone slips.

How do teams choose the right project management support?

Support should match the gap. A biotech organisation with strong internal ownership may need a time-limited coordinator. That person sets an integrated schedule and a reporting rhythm. A programme with many linked workstreams may need embedded project leadership. That role keeps actions moving, facilitates decisions, and surfaces risks. An organisation building wider governance may need foundational PMO processes alongside the programme work.

Before engaging support, executives can ask:

• What will the project manager own, and what stays with scientific, regulatory, quality, or executive leaders?
• Will the person work inside the team's existing tools and governance, or add a separate system?
• How will decisions, risks, dependencies, and changes be recorded?
• What cadence keeps functional leads informed without extra meetings?
• How will the work hand off after the meeting, including open actions?
• What experience fits this organisation's complexity, and how will support change as needs change?

There is no single delivery model. MustardSeed's PMO as a Service overview describes one way to structure ongoing support. Leaders can also review the project onboarding process and the company's project case studies. If the open question is which firm to hire, use a separate guide: Project Management Services: How to Choose a Partner. This article stays on the meeting plan itself. The right scope still comes from the programme's actual needs.

What should be in an executive readiness review?

A readiness review is most useful when it drives a decision instead of repeating a status presentation. The sponsor should get a short view of the purpose and the current forecast. The view should also cover important changes, risks, and the decisions required. Functional leads should be ready to explain their status. They should also explain the basis for any readiness call.

Use this comparison to tell the management products apart:

Ask each owner for the evidence behind a status and the next action. Also ask for the date of the next decision. If a readiness condition is open, name the consequence and the owner who will close it. If it cannot close in the planned window, the sponsor should hear the options. They should also hear the accountable experts' advice. A green label with no basis is less useful than a candid issue with a response plan.

Frequently asked questions about pre-IND readiness consulting

Do project management services decide what the team should ask FDA?

No. The organisation's regulatory and scientific leaders decide the meeting objectives, the question content, and the technical position. Project management services make that work visible. The team can see how decisions are developed, reviewed, approved, and coordinated.

When should a team begin readiness planning?

Begin when the organisation has a credible meeting objective. You also need enough programme context to name contributors and major dependencies. Lead time varies by programme and by the materials already in hand. Regulatory leaders should confirm the applicable procedures and timing. Update the project plan as assumptions change.

What if important evidence or decisions are still open?

Record the gap, its owner, and the action needed. Also record the decision date. Assess how it affects the meeting purpose and the connected work. Escalate material trade-offs to the right decision-makers. Leave scientific and regulatory judgements with the responsible experts.

Can a readiness dashboard certify that the team is ready for FDA?

No. A dashboard can show whether agreed management conditions are complete, open, or at risk. It cannot certify that scientific or regulatory content is adequate. That judgement stays with the qualified leads.

How is this different from choosing a project management partner?

Choosing a firm is a separate decision about fit, scope, and operating model. This article covers how the work is planned once the team is preparing for the meeting. For the selection question, read how to choose a project management services partner.

Related articles

• Biotech project management services for program leaders.
• Project management for FDA submission timelines.
• A clinical trial readiness checklist for PMO leaders.

Pre-IND readiness is strongest when scientific and regulatory expertise is backed by clear ownership, a realistic plan, visible decisions, and disciplined follow-through.

For contact details, see https://www.mustardseedpmo.com/contact-our-project-management-experts-mustardseed-pmo.